These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38672492)

  • 61. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.
    Leahy C; Osborne N; Shirota L; Rote P; Lee YK; Song BJ; Yin L; Zhang Y; Garcia V; Hardwick JP
    Biochem Pharmacol; 2024 Oct; 228():116241. PubMed ID: 38697309
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
    Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
    Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent insights on modulation of inflammasomes by adipokines: a critical event for the pathogenesis of obesity and metabolism-associated diseases.
    Pham DV; Park PH
    Arch Pharm Res; 2020 Oct; 43(10):997-1016. PubMed ID: 33078304
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses.
    Yi YS
    Immunology; 2017 Oct; 152(2):207-217. PubMed ID: 28695629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Causal Role of Mitochondrial Dynamics in Regulating Innate Immunity in Diabetes.
    Chang YH; Lin HY; Shen FC; Su YJ; Chuang JH; Lin TK; Liou CW; Lin CY; Weng SW; Wang PW
    Front Endocrinol (Lausanne); 2020; 11():445. PubMed ID: 32849261
    [No Abstract]   [Full Text] [Related]  

  • 69. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice.
    Burger K; Jung F; Baumann A; Brandt A; Staltner R; Sánchez V; Bergheim I
    Redox Biol; 2023 Oct; 66():102870. PubMed ID: 37683301
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model.
    Grandini NA; Costa MR; Gregolin CS; Siqueira JS; Vieira TA; Togneri Ferron AJ; Francisqueti-Ferron FV; Romualdo GR; Lúcia Dos Anjos Ferreira A; Aldini G; Corrêa CR; Moreto F
    Mol Cell Endocrinol; 2024 Mar; 582():112138. PubMed ID: 38147954
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
    Lee JH; Park J; Ahn SB
    Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression.
    Oh S; Baek YH; Jung S; Yoon S; Kang B; Han SH; Park G; Ko JY; Han SY; Jeong JS; Cho JH; Roh YH; Lee SW; Choi GB; Lee YS; Kim W; Seong RH; Park JH; Lee YS; Yoo KH
    Clin Mol Hepatol; 2024 Apr; 30(2):247-262. PubMed ID: 38281815
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Adipocitokines and nonalcoholic steatohepatitis].
    Lăcătuşu C; Mihai B; Cijevschi-Prelipcean C; Mihai C; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):882-9. PubMed ID: 20209757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.